Rivoceranib

Generic Name
Rivoceranib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H23N5O
CAS Number
811803-05-1
Unique Ingredient Identifier
5S371K6132
Background

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication

本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Phase 2
Not yet recruiting
Conditions
Relapsed Ovarian Cancer
Interventions
Drug: Fluzoparib
Drug: Apatinib
First Posted Date
2023-10-13
Last Posted Date
2023-10-13
Lead Sponsor
Jin Li
Target Recruit Count
54
Registration Number
NCT06081595

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

First Posted Date
2023-05-11
Last Posted Date
2023-05-11
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
244
Registration Number
NCT05854849
Locations
🇨🇳

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

First Posted Date
2023-05-10
Last Posted Date
2023-05-10
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT05853172
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

First Posted Date
2023-03-08
Last Posted Date
2024-02-06
Lead Sponsor
Fudan University
Target Recruit Count
145
Registration Number
NCT05759572
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

First Posted Date
2023-01-26
Last Posted Date
2024-05-01
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
130
Registration Number
NCT05699655
Locations
🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

Advanced or Metastatic Cholangiocarcinoma

Not Applicable
Not yet recruiting
Conditions
Cholangiocarcinoma
Interventions
Drug: Carrilizumab
Drug: Albumin-bound paclitaxel
Drug: Apatinib
First Posted Date
2022-12-16
Last Posted Date
2022-12-16
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
60
Registration Number
NCT05653817

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

First Posted Date
2022-10-26
Last Posted Date
2024-10-04
Lead Sponsor
Fudan University
Target Recruit Count
620
Registration Number
NCT05594095
Locations
🇨🇳

Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

First Posted Date
2022-10-17
Last Posted Date
2024-08-06
Lead Sponsor
Fudan University
Target Recruit Count
716
Registration Number
NCT05582499
Locations
🇨🇳

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

First Posted Date
2022-09-29
Last Posted Date
2022-11-09
Lead Sponsor
Ruijin Hospital
Target Recruit Count
116
Registration Number
NCT05559008
Locations
🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

First Posted Date
2022-07-07
Last Posted Date
2023-05-22
Lead Sponsor
West China Hospital
Target Recruit Count
35
Registration Number
NCT05447702
Locations
🇨🇳

West China Hospital, Sichuan University, Chengdu, Sichuan, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy